11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 29.10.2026 Expectation: 800 pips
Sell GBPUSD down to 1.3180
Yesterday at 12:02 PM 25
Period: 05.11.2026 Expectation: 300 pips
Buy Brent crude with $103 in sight
Yesterday at 12:02 PM 14
Gold sell
Period: 22.10.2026 Expectation: 180 pips
Gold sell-off targets $3,940
Yesterday at 11:16 AM 22
Period: 08.11.2026 Expectation: 6200 pips
Go short on USDJPY with 152.00 in view
Yesterday at 09:44 AM 33
Period: 29.10.2026 Expectation: 600 pips
EURUSD sell-off targets 1.1167
Yesterday at 05:56 AM 27
Period: 07.11.2026 Expectation: 6750 pips
Selling USDCAD down to 1.35500
07 October 2026 33
Go to forecasts